Matregen is a private company focused on the development and commercialization of novel Drug Delivery Systems (DDS), creating high value products for pharmaceutical companies in the chronic and palliative care markets.


Many existing pharmaceutical drugs fail to reach their full revenue potential because efficacy is compromised through sub-optimal strategies in delivery and administration. Hence patients and/or physicians often choose less painful or less toxic competitor products. Enabling delivery of potent, fragile, therapeutic agents where efficacy, compliance, convenience and safety are not compromised is of tremendous benefit to patients, clinicians and companies.

Matregen’s proprietary bio-polymer structures and matrices offer a truly unique alternative to the delivery of orally-toxic small molecules; and fragile, difficult-to-deliver “bioactive” molecules such as peptides.
  

Its lead proprietary technology -
DepotX™ - is in development for long-term (1-12 months), sub-cutaneous, high-loading, continuous-release, Minimum Efficacious Concentration (MEC) delivery solutions for Metabolic Diseases.


Matregen is partnering with companies who have compounds that require:
  • Improved Life Cycle Management and patent extension
  • Product differentiation and competitive advantage in crowded “me-too” markets
  • Localized delivery of highly potent compounds where toxicity must be carefully managed